Cutaneous Leishmaniasis, American Clinical Trial
Official title:
Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia: 2019-2021
NCT number | NCT05533736 |
Other study ID # | 201875 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2020 |
Est. completion date | December 1, 2021 |
Verified date | September 2022 |
Source | Centro Internacional de Entrenamiento e Investigaciones Médicas |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An effectiveness-implementation sequential explanatory hybrid design type 2 was performed in two rural communities of Colombia. A quasi-experimental study with historical control (standard of care) was designed to estimate the effectiveness of community-based intervention using the Guaral+ST mobile application (app). Three implementation outcomes were evaluated: acceptability and usability by qualitative methods, and fidelity by quantitative methods
Status | Completed |
Enrollment | 105 |
Est. completion date | December 1, 2021 |
Est. primary completion date | September 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Patients followed by CHL with the app (effectiveness evaluation): - Diagnosis confirmed by microscopy of tissue smear or culture - Any age and gender - Medical prescription for antileishmanial treatment - Approved and signed informed consent - Availability of CHL to monitor treatment of the patients in the community Inclusion Criteria patients who received the standard of care (effectiveness evaluation): - Clinical records of patients with confirmed CL at most two years prior to the start of this study - Any age and gender - Received antileishmanial treatment based on national guidelines Inclusion criteria for participants of implementation evaluation (Community Health Leaders) - Residents of the rural areas of study sites - Voluntary participation in the monitoring of patients using the mobile app |
Country | Name | City | State |
---|---|---|---|
Colombia | Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas | Cali | Valle |
Lead Sponsor | Collaborator |
---|---|
Centro Internacional de Entrenamiento e Investigaciones Médicas | Universidad Icesi |
Colombia,
Agarwal S, Perry HB, Long LA, Labrique AB. Evidence on feasibility and effective use of mHealth strategies by frontline health workers in developing countries: systematic review. Trop Med Int Health. 2015 Aug;20(8):1003-14. doi: 10.1111/tmi.12525. Epub 2015 May 14. Review. — View Citation
Carrion C, Robles N, Sola-Morales O, Aymerich M, Ruiz Postigo JA. Mobile Health Strategies to Tackle Skin Neglected Tropical Diseases With Recommendations From Innovative Experiences: Systematic Review. JMIR Mhealth Uhealth. 2020 Dec 31;8(12):e22478. doi: 10.2196/22478. — View Citation
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. — View Citation
Mieras LF, Taal AT, Post EB, Ndeve AGZ, van Hees CLM. The Development of a Mobile Application to Support Peripheral Health Workers to Diagnose and Treat People with Skin Diseases in Resource-Poor Settings. Trop Med Infect Dis. 2018 Sep 15;3(3). pii: E102. doi: 10.3390/tropicalmed3030102. — View Citation
Navarro A, Rubiano L, Arango JD, Rojas CA, Alexander N, Saravia NG, Aronoff-Spencer E. Developing mobile health applications for neglected tropical disease research. PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006791. doi: 10.1371/journal.pntd.0006791. eCollection 2018 Nov. Review. — View Citation
Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, Cisse M, Diro E, Fernandes Cota G, Erber AC, Gadisa E, Handjani F, Khamesipour A, Llanos-Cuentas A, López Carvajal L, Grout L, Lmimouni BE, Mokni M, Nahzat MS, Ben Salah A, Ozbel Y, Pascale JM, Rizzo Molina N, Rode J, Romero G, Ruiz-Postigo JA, Gore Saravia N, Soto J, Uzun S, Mashayekhi V, Vélez ID, Vogt F, Zerpa O, Arana B. Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. PLoS Negl Trop Dis. 2018 Jan 12;12(1):e0006141. doi: 10.1371/journal.pntd.0006141. eCollection 2018 Jan. — View Citation
Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011 Mar;38(2):65-76. doi: 10.1007/s10488-010-0319-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The effectiveness of community-based intervention using the Guaral+ST mobile application was evaluated by four outcomes: i. The number of follow-ups | The number of follow-up contacts between patients and health system or community health workers. | 6 months | |
Primary | ii. Percent adherence to treatment | Relation between the number of doses administrated and the number of doses formulated by the physicians x 100. | 6 months | |
Primary | iii. Adverse drug reactions | Frequency of adverse drug reactions: number of adverse drug reactions | 6 months | |
Primary | iv. Therapeutic response | Cure: Completely re-epithelialised lesions on days 90 -180 after initiation of treatment
Failure: >50% increase in ulcer size from baseline at any time during evaluation or incomplete re-epithelialised on days 90-180 |
6 months | |
Secondary | Implementation of the community-based strategy to follow patients with cutaneous Leishmaniasis was evaluated by three outcomes. i. Acceptability | It refers to the perception among implementation stakeholders that the app is appealing, suitable, or satisfactory by a qualitative evaluation at three levels: community health leaders, health workers, and, and patients. | 6 months | |
Secondary | ii. Usability | Refers to the degree to which the app can be used by community health leaders and health workers to achieve quantified objectives of effectiveness, efficiency, and satisfaction. It was evaluated using qualitatively at two levels: community health leaders and health workers. | 6 months | |
Secondary | iii. Fidelity | It refers to the compliance (percentage) with the implementation strategy as described in the protocol. It was measured at two levels: Community Health Leaders and physicians. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06011343 -
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Completed |
NCT06449040 -
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
|
Phase 1/Phase 2 | |
Completed |
NCT06000514 -
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
|
Phase 1/Phase 2 | |
Completed |
NCT03829917 -
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
|
Phase 2/Phase 3 |